About GEN Biotechnology

Aims & Scope

The biotech industry is booming, with records being set across the board – the annual number of new drugs winning approval; the number of companies going public; the number of professionals working in biotech; the amount of funding; and the new technologies fueling further progress and innovation in the industry. New technologies such as CRISPR have sparked an entire sub-industry around genome editing, leading to cures for devastating diseases less than a decade post development. From next-gen sequencing and organs-on-chips to synthetic biology and spatial biology, the list goes on.

GEN Biotechnology is the new peer-reviewed journal from Mary Ann Liebert, Inc. and Genetic Engineering & Biotechnology News (GEN) delivering exceptional research breakthroughs, news, and analysis directly impacting biotech. Published bimonthly in print and online with flexible open access options, the Journal provides a dynamic forum aimed at unifying both traditional academic audiences and executives and researchers from across the industry.